Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0767 Monotherapy Study in Type 2 Diabetes
NCT00543517Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2003
- Primary completion
- Nov 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of MK-767 in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoint: Hemoglobin A1c at 20 weeks. Started Feb 2003; status: terminated.
02
Drugs
MK-767
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00543517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543517.